Mary Dibiase Sells 67,695 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Mary Dibiase sold 67,695 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

X4 Pharmaceuticals Stock Up 2.3 %

Shares of XFOR stock traded up $0.01 during trading hours on Tuesday, hitting $0.54. 2,100,304 shares of the company’s stock traded hands, compared to its average volume of 2,129,799. The stock’s fifty day simple moving average is $0.68 and its two-hundred day simple moving average is $0.90. X4 Pharmaceuticals, Inc. has a 12-month low of $0.51 and a 12-month high of $1.60. The stock has a market cap of $90.85 million, a price-to-earnings ratio of -0.77 and a beta of 0.36. The company has a quick ratio of 6.04, a current ratio of 6.07 and a debt-to-equity ratio of 0.79.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.03). The firm had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $52.98 million. During the same period last year, the firm earned ($0.33) EPS. On average, analysts expect that X4 Pharmaceuticals, Inc. will post -0.65 EPS for the current year.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in X4 Pharmaceuticals in the 3rd quarter worth approximately $37,000. AQR Capital Management LLC raised its holdings in X4 Pharmaceuticals by 1,080.3% in the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after acquiring an additional 388,115 shares during the last quarter. K2 Principal Fund L.P. purchased a new position in X4 Pharmaceuticals in the 2nd quarter worth approximately $284,000. Ensign Peak Advisors Inc raised its holdings in X4 Pharmaceuticals by 4.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock worth $1,477,000 after acquiring an additional 111,032 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in X4 Pharmaceuticals in the 2nd quarter worth approximately $65,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of X4 Pharmaceuticals in a report on Friday, June 28th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.